Full-Time

Quantitative Developer

Idea Team

Updated on 6/24/2026

Wellington Management

Wellington Management

1,001-5,000 employees

Global asset management for institutional clients

No salary listed

Company Historically Provides H1B Sponsorship

Boston, MA, USA + 1 more

More locations: New York, NY, USA

Hybrid

Four days in office per week, one remote day.

Category
Quantitative Finance
Software Engineering
Required Skills
Python
Software Testing
Git
SQL
Pandas
NumPy
Snowflake
Requirements
  • Strong hands-on experience with Python for data-intensive applications, including use of common libraries (e.g., pandas, polars, numpy) and building testable, maintainable, production-quality code.
  • Solid understanding of data modeling concepts, particularly for time-series and reference data (e.g. slowly changing dimensions, point-in-time and bi-temporal data).
  • Proficiency with SQL and experience working with large datasets in modern data platforms (e.g., Snowflake, cloud data warehouses, data lakes) and open-source formats such as parquet.
  • Strong software engineering fundamentals: version control (git), code reviews, unit/integration testing, logging, and documentation.
  • Working knowledge of investment data, including: Security master and symbology (e.g., issuer vs. security identifiers, vendor symbologies).
  • Fundamental data (e.g., financial statements, estimates), pricing and returns, benchmarks, and basic risk/portfolio concepts.
  • Familiarity with the practical use of data in investment workflows such as screening, backtesting, portfolio analysis, factor, and performance / attribution concepts.
  • 3-7 years of professional experience as a quantitative developer, quantitative analyst, or research platform/analytics engineer in asset management, a hedge fund, or a similarly data-driven financial environment.
  • Bachelor’s degree in Computer Science, Engineering, Mathematics, Statistics, or a related quantitative field, or equivalent professional experience.
Responsibilities
  • Design and implement robust data models for securities, issuers, fundamentals, time series, and analytics across multiple asset classes (e.g., equity, fixed income, macro).
  • Develop and maintain Python-based libraries and services that provide consistent, well-documented access to research data and analytics.
  • Partner with data engineering to ensure upstream data and pipelines support analytics needs.
  • Collaborate with investors and quantitative researchers to understand their workflows and translate requirements into scalable data and tooling solutions.
  • Contribute to the rationalization of data vendors and the convergence of legacy data stores into a cohesive, central platform capability.
  • Implement and enhance data and analytics quality controls, monitoring, and documentation to promote trust in both the data and the analytics built on top of it.
  • Participate in code reviews, design discussions, and standards-setting to ensure high engineering quality and reusability across the platform.
  • Proactively identify opportunities to improve performance, usability, and reliability of the platform, and drive initiatives from concept through to adoption.
Wellington Management

Wellington Management

View

Wellington Management is a global investment management firm that offers equity, fixed income, multi-asset, and alternative investments to both institutional clients (such as pension funds, endowments, foundations, and insurers) and individual investors. It manages assets on behalf of clients, earning fees based on assets under management (AUM) and on investment performance. The firm relies on deep research capabilities and market insights to tailor investment strategies that meet client needs, and it integrates environmental, social, and governance (ESG) factors into its process. What sets Wellington Management apart is its broad suite of investment options combined with a commitment to ESG integration and a client-tailored approach, supported by a culture that emphasizes diversity and inclusion. The company’s goal is to help clients achieve their investment objectives by delivering disciplined, research-driven strategies and sustainable investing over the long term.

Company Size

1,001-5,000

Company Stage

N/A

Total Funding

$61.8B

Headquarters

Boston, Massachusetts

Founded

1933

Your Connections

People at Wellington Management who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • $1.3T platform supports cross-sell across institutional and wealth channels.[2][4]
  • Hartford Funds acquisition adds advisor distribution and strengthens US Wealth reach.[3]
  • Liquid alternatives and sustainable outcomes provide differentiated product demand.[1][3]

What critics are saying

  • AUM-linked fees fall quickly during market drawdowns and passive outflows.[3]
  • Hartford integration risks disrupt systems, talent retention, and client relationships.[3]
  • Regulatory approval delays can postpone or derail the Hartford transaction.[3]

What makes Wellington Management unique

  • Independent private partnership with globally integrated, research-driven boutiques.[3][6]
  • Broad platform spans equity, fixed income, alternatives, and multi-asset solutions.[2][3]
  • Long client relationships and local presence across major financial centers.[2][4]

Help us improve and share your feedback! Did you find this helpful?

Benefits

Comprehensive health coverage

Work-life balance

Financial future

Development

Company News

Radio Intereconomía
Apr 14th, 2026
Wellington launches global market neutral fund to capture alpha in volatile environment

Wellington Management has launched the Wellington Absolute Return Global Equity Fund, a UCITS vehicle employing a global market neutral strategy aimed at generating returns above cash with limited exposure to traditional markets. The fund expands Wellington's liquid alternatives offering. The launch comes amid increased market volatility and reduced stability, positioning the fund to capture alpha in challenging conditions through its market-neutral approach to global equities.

AD HOC NEWS Portal Aktiengesellschaft
Apr 12th, 2026
Wellington buys 5% stake in Renk as $339M in delayed defence contracts weigh on cash flow

Wellington Management has acquired a 5.09% stake in German defence supplier Renk Group, signalling confidence despite the company facing significant operational challenges. The US asset manager built its position through direct share purchases and equity swaps. Renk is currently contending with approximately €300 million in blocked revenue due to delayed deliveries and missing export licenses. Around €200 million in planned sales has been pushed to 2026, whilst €80-100 million in orders for Israeli tank gearbox systems await German export approval. The cash flow pressure is evident, with free cash flow reaching only €67 million last fiscal year, well below the company's 80% conversion target. Shares fell 4.34% to €52.05, extending year-to-date losses to nearly 6%. Despite near-term challenges, Renk maintains a record order backlog of €6.68 billion.

Voyager Therapeutics
Apr 10th, 2026
Voyager Therapeutics Raises $60 Million in Oversubscribed Series B Financing | Voyager Therapeutics Inc.

Gene Therapy Leader to Advance Broad Product Pipeline & AAV Product Engine   Cambridge, Mass., April 13, 2015 – Voyager Therapeutics , a gene therapy company developing life-changing treatments for fatal and debilitating diseases of the central nervous system (CNS), today announced the successful

Business Wire
Apr 2nd, 2026
Cyclerion Therapeutics and Korsana Biosciences Announce Merger Agreement

Cyclerion Therapeutics, Inc. (“Cyclerion”) (Nasdaq: CYCN) and Korsana Biosciences, Inc. (“Korsana”), a privately-held biotechnology company discovering and d...

医谷网
Mar 23rd, 2026
London gene therapy firm NightstaRx raises $45M to advance blindness treatment trials

NightstaRx, a London-based ophthalmology company developing gene therapies for inherited retinal diseases, has raised $45 million in Series C funding. Wellington Management Company and Redmile Group led the round, with participation from existing investors Syncona and New Enterprise Associates. Founded in 2013, Nightstar has four drug candidates targeting conditions including choroideremia, X-linked retinitis pigmentosa and macular degeneration. Its lead candidate, NSR AAV-REP1, uses an adeno-associated virus vector to deliver the REP-1 gene to retinal cells, potentially offering a one-time treatment for choroideremia, which causes progressive blindness. The therapy is currently in phase 1/2 trials, with positive results from 14 patients published in The Lancet. The funding will advance NSR AAV-REP1 into phase 3 trials and progress two other candidates into phase 1/2 studies.